Table 2 Clinical response to IFN-beta treatment in MS patients with a decrease of MHC2TA mRNA levels and HHV-6 in serum (at least once among the five programmed visits) vs. MS patients with an increase of MHC2TA mRNA level and without HHV-6 in serum, after two years of IFN-beta treatment
IFN-beta clinical response | EDSS* | Relapses** | |||
|---|---|---|---|---|---|
N | Resp. | % | |||
MHC2TA mRNA level decreased + HHV-6 in serum | 21 | 5 | 23.8 | 1.5 | 1.2 |
MHC2TA mRNA level increased without HHV-6 in serum | 99 | 58 | 58.6 | - 0.5 | 0.4 |
p | 0.004 | ||||